Clinical trial · Observational
Signaling Pathways Targeting Colorectal Cancer in Egypt
Identification of New Signaling Pathways Targeting Colorectal Cancer in Egyptian Patients
NCT03467308CI-TRIAL-00045038completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. In Egypt, CRC constitutes 4.2% of all cancers with median age is 50 years old.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH) | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Colorectal cancer patients
- description
- 50 Patients confirmed histopathologically to have early stages of colorectal cancer.
- interventionNames
- Genetic: Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)
- label
- Risky group
- description
- 20 risky patients (those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
- interventionNames
- Genetic: Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)
Primary outcomes (2)
- measure
- Measure TIGAR in the study groups.
- timeFrame
- 1 YEAR
- description
- Measure TIGAR expression in colorectal cancer patients and risky group patients.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * All Patients confirmed histopathologically to have early stages of colorectal cancer. * Risky group patients (including those with ulcerative colitis, chron's disease, familial adenomatous polyposis). Exclusion Criteria: * Patients with previous history of CRC treated with chemotherapy or presence of other types of cancer.
References
Publications (9)
- BACKGROUNDYang J, Wen J, Tian T, Lu Z, Wang Y, Wang Z, Wang X, Yang Y. GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer. Oncotarget. 2017 Feb 14;8(7):11788-11796. doi: 10.18632/oncotarget.14352. PMID 28052033
- BACKGROUNDCheung EC, Athineos D, Lee P, Ridgway RA, Lambie W, Nixon C, Strathdee D, Blyth K, Sansom OJ, Vousden KH. TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell. 2013 Jun 10;25(5):463-77. doi: 10.1016/j.devcel.2013.05.001. Epub 2013 May 30. PMID 23726973
- BACKGROUNDWon KY, Lim SJ, Kim GY, Kim YW, Han SA, Song JY, Lee DK. Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer. Hum Pathol. 2012 Feb;43(2):221-8. doi: 10.1016/j.humpath.2011.04.021. Epub 2011 Aug 4. PMID 21820150
- BACKGROUNDZhao M, Fan J, Liu Y, Yu Y, Xu J, Wen Q, Zhang J, Fu S, Wang B, Xiang L, Feng J, Wu J, Yang L. Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-kappaB pathway modulation. Int J Oncol. 2016 Feb;48(2):756-64. doi: 10.3892/ijo.2015.3297. Epub 2015 Dec 17. PMID 26691054
- BACKGROUNDZhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH, Gao WQ. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53. Gastroenterology. 2014 Nov;147(5):1043-54. doi: 10.1053/j.gastro.2014.07.021. Epub 2014 Jul 18. PMID 25046164
- BACKGROUNDLiang J, Xing D, Li Z, Shen J, Zhao H, Li S. TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma. Mol Med Rep. 2016 Jun;13(6):5200-6. doi: 10.3892/mmr.2016.5183. Epub 2016 Apr 25. PMID 27121462
- BACKGROUNDZhan W, Han T, Zhang C, Xie C, Gan M, Deng K, Fu M, Wang JB. TRIM59 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Upregulating Cell Cycle Related Proteins. PLoS One. 2015 Nov 24;10(11):e0142596. doi: 10.1371/journal.pone.0142596. eCollection 2015.